Palo Alto, CA, United States of America

Michael Tracy


Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 75(Granted Patents)


Location History:

  • Menlo Park, CA (US) (1987)
  • Palo Alto, CA (US) (1992 - 2004)

Company Filing History:


Years Active: 1987-2004

Loading Chart...
7 patents (USPTO):

Title: Michael Tracy: Innovator in Radiosensitization

Introduction

Michael Tracy is a notable inventor based in Palo Alto, CA. He has made significant contributions to the field of radiosensitization, holding a total of 7 patents. His work focuses on developing novel compounds that enhance the effectiveness of radiation therapy in treating tumors.

Latest Patents

One of his latest patents involves the use of 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents. This method discloses the use of these compounds to specifically radiosensitize hypoxic tumor cells. Additionally, some of these compounds are identified as effective cytotoxic agents for these cells. Remarkably, they also demonstrate an unexpected ability to radiosensitize aerobic cells after or before a hypoxic incubation with the drug. This discovery provides a foundation for selectively radiosensitizing tumors while sparing normal cells. Furthermore, a novel method for preparing the 1,2,4-benzotriazine oxides is also included in this patent.

Career Highlights

Michael Tracy is associated with SRI International, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on cancer treatment and patient outcomes.

Collaborations

Some of his notable coworkers include William W. Lee and J. Martin Brown, who have collaborated with him on various projects.

Conclusion

Michael Tracy's innovative work in the field of radiosensitization highlights his commitment to improving cancer therapies. His contributions are paving the way for more effective treatments that could significantly benefit patients in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…